Trial Profile

A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary) ; Cemiplimab (Primary)
Indications Skin cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms EMPOWER-CSCC 1; R2810-ONC-1540
Sponsors Regeneron Pharmaceuticals; Sanofi

Most Recent Events

08 Mar 2024 This study has been Completed in Italy, According to European Clinical Trials Database record.
17 Nov 2023 Status changed from active, no longer recruiting to completed.
13 Sep 2022 Results from group 6 (n=165, as of data cut off date of Oct 25 2021) assessing additional efficacy and safety presented at the 47th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com